A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study with an open-label period and long-term extension to assess the efficacy and safety of rilzabrutinib in participants with warm autoimmune hemolytic anemia (wAIHA)

16383EFC17360OpenA phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study with an open-label period and long-term extension to assess the efficacy and safety of rilzabrutinib in participants with warm autoimmune hemolytic anemia (wAIHA)NCT07086976IndustrialAdultTreatmentIIIOtherBroome, CatherineGeorgetown University Medical Center; Lombardi Comprehensive Cancer CenterGUMC Medicine Hem-Onc2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>